Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Draft Guideline on Lifecycle Management Reaches Agreement at ICH Meeting in Montreal
June 22, 2017
- JMA Plans Chuikyo Rep Reshuffle, Nakagawa Likely to Bow Out
June 21, 2017
- PMDA Beats FY2016 Review Time Targets
June 16, 2017
- CDISC-Based Electronic Submissions for 24 Products in FY2016: PMDA
June 16, 2017
- 15.3 Billion Yen to Be Allocated to 30 Projects to Promote R&D in Field of Healthcare
June 16, 2017
- MHLW Panel Recommends Moving Ahead with Discussions toward Easing Regulations on Export of Blood Products
June 16, 2017
- MHLW Tries to Give Full Picture of Envisaged “CEA” Scheme with Hypothetical Drug: Chuikyo
June 15, 2017
- 1st Generics for 13 APIs to Join NHI Price List on June 16; Micardis, Abilify Face Competition
June 15, 2017
- Daiichi Sanko Espha Skips June Listing for Rezaltas, Gracevit AGs
June 15, 2017
- Chuikyo Reps Agree on Revisiting Discrepancy Rate Cutoff for Price Maintenance Premium
June 15, 2017
- Chuikyo Members Want to Stick to Pilot-Based Premium, at Odds with Industry
June 15, 2017
- (Update) Add’l Eligibility Criteria Proposed for Companies to Get Price Maintenance Premium, Tiered Premiums Eyed: Chuikyo
June 15, 2017
- Chuikyo OKs Plan for FY2017 Drug Price Survey
June 14, 2017
- Add’l Eligibility Criteria Proposed for Companies to Get Price Maintenance Premium: Chuikyo
June 14, 2017
- PMDA Provides Relief for Over 100 Health Damage Cases Tied to HPV Vaccines: FY2016
June 13, 2017
- MHLW Panel Gives Thumbs-Up for Nusinersen, Tenelia-Canaglu Combo
June 12, 2017
- MHLW Study Group on Counterfeit Drugs to Discuss Issues such as GDP Later This Fiscal Year
June 12, 2017
- Govt’s Regulatory Reform Plan Embraces Review of 14-Day Prescription Limit
June 12, 2017
- MHLW Study Group Compile Draft Interim Report on Preventing Distribution of Counterfeit Drugs
June 12, 2017
- Japan Cabinet Adopts 2017 Honebuto Policy
June 12, 2017
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…